PDF(Pubmed)
Abstract：
The advancement of renal replacement therapy has significantly enhanced the survival rates of patients with end-stage renal disease (ESRD) over time. However, this prolonged survival has also been associated with a higher likelihood of cancer diagnoses among these patients including breast cancer. Breast cancer treatment typically involves surgery, radiation, and systemic therapies, with approaches tailored to cancer type, stage, and patient preferences. However, renal replacement therapy complicates systemic therapy due to altered drug clearance and the necessity for dialysis sessions. This review emphasizes the need for optimized dosing and administration strategies for systemic breast cancer treatments in dialysis patients, aiming to ensure both efficacy and safety. Additionally, challenges in breast cancer screening and diagnosis in this population, including soft-tissue calcifications, are highlighted.
摘要：
随着时间的推移，肾脏替代疗法的发展显着提高了终末期肾病（ESRD）患者的生存率。然而,在包括乳腺癌在内的这些患者中,这种延长的生存期也与更高的癌症诊断可能性相关.乳腺癌治疗通常包括手术，辐射,和全身疗法，针对癌症类型定制的方法，舞台,和患者偏好。然而,由于药物清除改变和透析治疗的必要性,肾脏替代治疗使全身治疗复杂化.这篇综述强调了透析患者全身乳腺癌治疗需要优化的给药和给药策略。旨在确保疗效和安全性。此外,在这一人群中乳腺癌筛查和诊断的挑战，包括软组织钙化,被突出显示。
